Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 242,900 shares, a growth of 6.9% from the February 29th total of 227,200 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average trading volume of 75,100 shares, the days-to-cover ratio is currently 3.2 days.
Eton Pharmaceuticals Trading Down 2.2 %
ETON opened at $3.60 on Thursday. The firm has a market capitalization of $92.48 million, a PE ratio of -120.00 and a beta of 1.17. Eton Pharmaceuticals has a twelve month low of $2.42 and a twelve month high of $5.81. The firm’s 50-day moving average price is $4.27 and its 200 day moving average price is $4.20.
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The business had revenue of $7.31 million for the quarter, compared to analyst estimates of $7.70 million. Eton Pharmaceuticals had a negative return on equity of 6.21% and a negative net margin of 2.96%. As a group, analysts predict that Eton Pharmaceuticals will post 0.26 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Eton Pharmaceuticals
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Eton Pharmaceuticals in a research report on Monday, December 11th.
Check Out Our Latest Report on Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
See Also
- Five stocks we like better than Eton Pharmaceuticals
- Industrial Products Stocks Investing
- What is a Bull Market? Key Information about Bull Markets
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
- How to Evaluate a Stock Before Buying
- Dave & Buster’s Stock Value Is Unleashed, Not Too Late To Get In
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.